About the VHIR
Here at the Vall d'Hebron Research Institute (VHIR) we promote biomedical research, innovation and teaching. Over 1,800 people are seeking to understand diseases today so the treatment can be improved tomorrow.
Research
We are working to understand diseases, to find out how they operate and to create better treatments for patients. Get to know about our groups and their lines of research.
People
People are the centre of the Vall d'Hebron Research Institute (VHIR). This is why we are bound by the principles of freedom of research, gender equality and professional attitudes that HRS4R promotes.
Clinical trials
Our work is not just basic or translational; we are leaders in clinical research. Enter and find about the clinical trials we are conducting and why we are a world reference in this field.
Progress
Our aim is to make the research carried out at the Vall d’Hebron Research Institute (VHIR) a driving force for transformation. How? By identifying new channels and solutions for the promotion of people's health and well-being.
Core facilities
We offer specialist support for researchers, internal and external alike, ranging from specific services to preparing complete projects. All this, from a perspective of quality and speed of response.
News
We offer you a gateway for staying up to date on everything going on at the Vall d’Hebron Research Institute (VHIR), from the latest news to future solidarity activities and initiatives that we are organising.
The Diabetes and Metabolism Research Group is search is lead by Dr. Rafael Simó (Hirsch index:54), Head of the Endocrinology Department, Professor of Medicine & Endocrinology at UAB and current President of the European Association for the Study of Diabetes-Eye Complications. The group consists of 7 senior clinical investigators, 4 basic post-doctoral researchers, 4 pre-doc researchers, 3 laboratory technicians and one coordinator of clinical assays.
The group belongs to “CIBER” of Diabetes and Associated Metabolic Diseases (CIBERDEM. ISCIII) and has been recognized as consolidated group by the Generalitat de Catalunya (AQU/AGAUR).
Since 2014 this group has been qualified as outstanding in the evaluations performed by the ANEP, CIBERDEM and the external Scientific Advisory Board of VHIR.
The main lines of research are:
PMID: 35625751 Journal: Biomedicines Year: 2022 Reference: Biomedicines. 2022 Apr 28;10(5). pii: biomedicines10051015. doi: 10.3390/biomedicines10051015. Impact factor: 6.081 Publication type: Paper in international publication Authors: Gabriel-Medina, Pablo, Ferrer-Costa, Roser, Rodriguez-Frias, Francisco, Ciudin, Andreea, Augustin, Salvador, Rivera-Esteban, Jesus, Pericas, Juan M, Selva, David Martinez et al. DOI: 10.3390/biomedicines10051015
PMID: 35600617 Journal: Frontiers in Neuroscience Year: 2022 Reference: Front Neurosci. 2022 May 5;16:858049. doi: 10.3389/fnins.2022.858049. eCollection 2022. Impact factor: 4.677 Publication type: Paper in international publication Authors: Khalangot, Mykola D, Hernandez, Cristina, Nilsson, Peter M, Simo, Rafael, Artner, Isabella, Lyssenko, Valeriya, Chan, Juliana, Vaag, Allan, Kravchenko, Victor, Fedotkina, Olena et al. DOI: 10.3389/fnins.2022.858049
PMID: 34042029 Journal: CURRENT MEDICINAL CHEMISTRY Year: 2022 Reference: Curr Med Chem. 2022;29(12):2189-2199. doi: 10.2174/0929867328666210526114417. Impact factor: 4.53 Publication type: Paper in international publication Authors: Simo-Servat, Olga, Ramos, Hugo, Bogdanov, Patricia, Garcia-Ramirez, Marta, Huerta, Jordi, Hernandez, Cristina, Simo, Rafael et al. DOI: 10.2174/0929867328666210526114417
PMID: 35453934 Journal: Diagnostics Year: 2022 Reference: Diagnostics (Basel). 2022 Apr 1;12(4). pii: diagnostics12040886. doi: 10.3390/diagnostics12040886. Impact factor: 3.706 Publication type: Paper in international publication Authors: Gabriel-Medina, Pablo, Diaz-Troyano, Noelia, Barquin-DelPino, Raquel, Castillo-Ribelles, Laura, Esteban, Angels, Hernandez-Gonzalez, Manuel, Ferrer-Costa, Roser, Pumarola, Tomas, Rodriguez-Frias, Francisco, Klammer, Martin et al. DOI: 10.3390/diagnostics12040886
PMID: 34238673 Journal: Hipertension y riesgo vascular Year: 2021 Reference: Hipertens Riesgo Vasc. 2021 Oct-Dec;38(4):201-205. doi: 10.1016/j.hipert.2021.05.003. Epub 2021 Jul 6. Impact factor: 0 Publication type: Letter or abstract Authors: Bury, R, Leon Roman, J, Casteras, A, Vergara, A, Biagetti, B, Garcia-Carro, C, Cordero-Vazquez, E, Hernandez Hernandez, I, Agraz, I, Soler, M J et al. DOI: 10.1016/j.hipert.2021.05.003
PMID: 34242330 Journal: PLoS One Year: 2021 Reference: PLoS One. 2021 Jul 9;16(7):e0254243. doi: 10.1371/journal.pone.0254243. eCollection 2021. Impact factor: 3.24 Publication type: Paper in international publication Authors: Llorens-Revull, Meritxell, Costafreda, Maria Isabel, Rico, Angie, Guerrero-Murillo, Mercedes, Soria, Maria Eugenia, Piriz-Ruzo, Sofia, Vargas-Accarino, Elena, Gabriel-Medina, Pablo, Rodriguez-Frias, Francisco, Riveiro-Barciela, Mar et al. DOI: 10.1371/journal.pone.0254243
PMID: 34104210 Journal: Therapeutic Advances in Gastroenterology Year: 2021 Reference: Therap Adv Gastroenterol. 2021 May 30;14:17562848211016567. doi: 10.1177/17562848211016567. eCollection 2021. Impact factor: 4.409 Publication type: Paper in international publication Authors: Campos-Varela, Isabel, Villagrasa, Ares, Simon-Talero, Macarena, Riveiro-Barciela, Mar, Ventura-Cots, Meritxell, Aguilera-Castro, Lara, Alvarez-Lopez, Patricia, Nordahl, Emilie A, Rivera-Esteban, Jesus M, Romero, Alba et al. DOI: 10.1177/17562848211016567
PMID: 34032928 Journal: ACTA DIABETOLOGICA Year: 2021 Reference: Acta Diabetol. 2021 Oct;58(10):1403-1412. doi: 10.1007/s00592-021-01735-5. Epub 2021 May 25. Impact factor: 4.28 Publication type: Paper in international publication Authors: Planas, Alejandra, Simo-Servat, Olga, Baneras, Jordi, Sanchez, Monica, Garcia, Esther, Ortiz, Angel M, Ruiz-Meana, Marisol, Hernandez, Cristina, Ferreira-Gonzalez, Ignacio, Simo, Rafael et al. DOI: 10.1007/s00592-021-01735-5
The European project, in which Vall d'Hebron participates, will favor personalized diagnosis and innovative therapeutic strategies in patients with the disease.
This investment from EIT Health in the project will enable D-Sight to progress in the clinical development of its groundbreaking treatment for the early stages of diabetic retinopathy.
This initiative of the ”la Caixa” Foundation offers the selected entrepreneurial scientists financial support and support through individual mentoring and training.
